![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
Aug. 5th, 2014
Ebola drug
Aug. 5th, 2014 11:35 amCеверо-американский винегрет :)
* The unlicenced drug, called ZMapp, is made of three monoclonal antibodies
* Two of the monoclonal antibodies are the product of years of research done at the Public Health Agency of Canada’s National Microbiology Laboratory in Winnipeg
* The third was developed at the U.S. Army Medical Research Institute of Infectious Diseases
* The Canadian research was done under the leadership of Dr. Gary Kobinger who heads the special pathogens research program at the national laboratory. His team had developed a cocktail of three monoclonal antibodies called ZMAb, the rights to which were recently acquired by LeafBio of San Diego, Calif.
* LeafBio is collaborating with Mapp Biopharmaceutical, also of San Diego, which is the maker of ZMapp. A joint statement from Mapp Biopharmaceutical and LeafBio said ZMapp is an optimized monoclonal cocktail, incorporating the best of the Canadian and U.S.-made antibodies
* The drug is generated in tobacco plants that have been genetically engineered to produce the monoclonal antibodies. That work is done by Kentucky BioProcessing of Owensboro, KY., a subsidiary of tobacco giant Reynolds American.
Source - full article
* The unlicenced drug, called ZMapp, is made of three monoclonal antibodies
* Two of the monoclonal antibodies are the product of years of research done at the Public Health Agency of Canada’s National Microbiology Laboratory in Winnipeg
* The third was developed at the U.S. Army Medical Research Institute of Infectious Diseases
* The Canadian research was done under the leadership of Dr. Gary Kobinger who heads the special pathogens research program at the national laboratory. His team had developed a cocktail of three monoclonal antibodies called ZMAb, the rights to which were recently acquired by LeafBio of San Diego, Calif.
* LeafBio is collaborating with Mapp Biopharmaceutical, also of San Diego, which is the maker of ZMapp. A joint statement from Mapp Biopharmaceutical and LeafBio said ZMapp is an optimized monoclonal cocktail, incorporating the best of the Canadian and U.S.-made antibodies
* The drug is generated in tobacco plants that have been genetically engineered to produce the monoclonal antibodies. That work is done by Kentucky BioProcessing of Owensboro, KY., a subsidiary of tobacco giant Reynolds American.
Source - full article